An ovary autotransplanted into the spleen of a bilaterally ovariectomized rat develops into a
luteoma, which grows under constant
gonadotropin hyperstimulation. The effect of a long-acting
GnRH agonist (
GnRH-a), on
tumor growth and
hormone secretion was investigated. Two experimental models were used: Model 1:
GnRH-a (0.33 mg/rat sc) or
estradiol valerianate (50 micrograms/rat sc injected once a week for four weeks) was administered simultaneously with ovary implantation; Model 2: the drugs were administered after 1 month of
tumor development. The treatment with
estradiol was used as a control of
tumor regression. Saline injected ovarian grafted rats and
Sham operated animals were used as controls. In Model 1: The
GnRH-a significantly inhibited
tumor development (Positive
tumors: Saline: 100% vs
GnRH-a: 43%, p < 0.01). In Model 2: the
GnRH-a and
estradiol significantly reduced the volume of one month old
tumors (52% and 39% of initial volumes respectively, p < 0.01).
Gonadotropin secretion was significantly inhibited or its increase blunted by the
GnRH-a and by
estradiol treatments in both models.
Estradiol and
progesterone in portal blood, which collects the
steroids secreted by the
luteoma, were significantly reduced by
GnRH-a treatment in both models. On the other hand, in tumor cells cultured "in vitro", the
GnRH-a was able to inhibit the LH induced
progesterone secretion in a concentration dependent way. These results clearly show that the
GnRH-a is effective in inhibiting
tumor growth or reducing its volume, when already developed; furthermore, it suppresses
tumor steroid hormone production. These actions were exerted at both the hypophyseal and
tumor levels.